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The inﬂuence of inhibitors of P-glycoprotein (verapamil [VE], cyclosporine [CY], and GF120918 [GF]) on
the cell handling of macrolides (erythromycin [ERY], clarithromycin [CLR], roxithromycin [ROX], azithro-
mycin [AZM], and telithromycin [TEL]) was examined in J774 murine macrophages. The net inﬂux rates of
AZM and TEL were increased from 2- to 3.5-fold in the presence of these inhibitors, but their efﬂux was slowed
only marginally. At 3 h, the inhibitors increased the levels of AZM, ERY, and TEL accumulation approximately
three- to fourfold (the effect of VE, however, was lower) but did not inﬂuence CLR accumulation (the inhibitors
had an intermediate behavior on ROX accumulation). The effect was concentration dependent (half-maximal
increases in the level of accumulation of AZM were obtained with GF, CY, and VE at 0.5, 5, and 10 M,
respectively). ATP depletion also caused an approximately threefold increase in the level of accumulation of
AZM. Two inhibitors of MRP (probenecid [2.5 mM] and gemﬁbrozil [0.25 mM]) had no effect. Monensin (a
proton ionophore) completely suppressed the accumulation of AZM in control cells as well as in cells incubated
in the presence of VE, demonstrating that transmembrane proton gradients are the driving force causing the
accumulation of AZM in both cases. Yet, VE did not alter the pH of the lysosomes (approximately 5) or of the
cytosol (approximately 7.1). P-glycoprotein was detected by immunostaining at the cell surface as well as in
intracellular vacuoles (endosomes and lysosomes). The data suggest that the inﬂux of AZM, ERY, TEL, and
ROX is adversely inﬂuenced by the activity of P-glycoprotein in J774 macrophages, resulting in suboptimal
drug accumulation.
Active drug transporters have been described in both pro-
caryotic and eucaryotic cells. Originally described as conferring
resistance to anticancer agents in cancer cells, antibiotics in
bacteria, or antifungal agents in fungi, these proteins appear
today to be part of a very general mechanism that cells have
developed to protect themselves from invasion by diffusible,
foreign molecules (for a review, see reference 37). In this
context, the occurrence of antibiotic transporters in eucaryotic
cells has become a common observation (7, 33). More specif-
ically, P-glycoprotein (also referred to as MDR1) and MRP,
which are expressed in most cell types and which transport a
large variety of drugs, have received much attention. These two
types of transporters belong to the superfamily of ATP binding
cassette transporters and use ATP hydrolysis as an energy
source (28). They play a key role in drug disposition by mod-
ulating drug transport through epithelia and other biological
barriers to an extent that was completely unsuspected only a
few years ago (1).
Focusing on macrolides, erythromycin has been shown to be
transported by P-glycoprotein in Caco-2 intestinal cells (29,
34). In parallel, erythromycin and azithromycin are capable of
inhibiting the transport of various substrates of the P-glyco-
protein in epithelial cells in vitro as well as in vivo (9, 12, 13, 23,
30, 31, 39). Yet, little is known about the role of efﬂux trans-
porters in the handling of macrolides by macrophages, in which
these drugs are known to accumulate in large amounts (2, 3,
20, 24).
In the present study, we have examined directly in macro-
phages the potential inﬂuence of P-glycoprotein and MRP on
the accumulation and efﬂux of ﬁve macrolides of clinical inter-
est. We used both broad-spectrum, nonspeciﬁc inhibitors of
P-glycoprotein (verapamil and cyclosporine) and MRP (pro-
benecid and gemﬁbrozil) and the speciﬁc P-glycoprotein mod-
ulator GF120918 (11, 15). We selected the murine J774 murine
macrophage line since much is already known about the dis-
positions of macrolides in these cells (2, 3, 36).
MATERIALS AND METHODS
Cells. We used J774 murine macrophages, which were cultivated as described
previously (25). Cell viability was assessed by measurement of lactate dehydro-
genase release (19).
Determination of cellular antibiotic accumulation. Studies of cellular antibi-
otic accumulation were performed by the general procedure described in previ-
ous publications (3, 25). Antibiotic assays were performed with cell lysates by the
diffusion disk method (17) with antibiotic medium 2 (Difco, Becton Dickinson &
Co., Sparks, Md.) seeded with Micrococcus luteus ATCC 9341. The pH of the
medium was adjusted to 9.5 for all drugs except azithromycin (for which the pHs
were adjusted to 9.5 for samples with drug concentrations 0.5 mg/liter and 8.0
for higher drug concentrations). The lowest limits of detection and the typical
ranges of drug concentrations measured were 0.2 and 0.9 to 4 mg/liter, respec-
tively, for erythromycin; 0.2 and 0.25 to 0.4 mg/liter, respectively, for roxithro-
mycin; 0.08 and 0.25 to 0.9 mg/liter, respectively, for azithromycin; 0.2 and 0.4 to
0.8 mg/liter, respectively, for clarithromycin; and 0.08 and 0.3 to 1.3 mg/liter,
respectively, for telithromycin. Linearity was obtained up to a concentration of
2 mg/liter for all drugs (the concentration at which linearity was obtained for
azithromycin at pH 8 was 32 mg/liter), with R
2 being 0.96 (n  18 for each
drug). Inter- and intraday coefﬁcients of variation for azithromycin were 5.3 and
2.2%, respectively. All assays were performed on plates 22.5 by 22.5 cm, with
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1047standards of the corresponding drug incubated on the same plate as the samples
(typically, six standards covering the observed range of concentrations of samples
were used, and these were tested in triplicate [similar inhibition zones were
observed for standards prepared in water or cell lysates]). The cell drug content
(cellular concentration) was systematically expressed by reference to the protein
content, and the apparent cellular concentration-to-extracellular concentration
ratio was determined by using a conversion factor of 5 l of cell volume per mg
of cell protein (2, 3).
Determination of cytosolic and lysosomal pHs. The pHs of intracellular com-
partments were measured with the speciﬁc ﬂuorescent probes 2-(4-pyridyl)-5-
{[4-(2-dimethylaminoethylamino-carbamoyl)methoxy]phenyl}oxazole dextran
(lysosensor yellow/blue-labeled dextran [LYBD] for lysosomes (5) and 2,7-bis-
(2-carboxyethyl)-5-(and -6)-carboxyﬂuorescein [BCECF] (26) for the cytosol.
Cells were incubated overnight with 2 mg of LYBD per ml or for1ha t3 7 °C with
2 M BCECF-AM (acetoxymethyl ester). The ﬂuorescence of LYBD was re-
corded at 515 nm upon successive excitation at 340 and 405 nm, and that of
BCECF was also recorded at 515 nm upon successive excitation at 440 and 490
nm (the ratio of the readings allows calculation of the local pH [5, 26]).
Confocal microscopy. Cells were incubated overnight with rhodamine B-la-
beled dextran (molecular weight, 10,000; 2.5 mg/ml) to vitally stain endosomes
and lysosomes, washed, and then used for immunolabeling of P-glycoprotein with
rabbit polyclonal anti-P-glycoprotein antibodies (12.5 mg/liter) and Alexa Fluor
488-labeled anti-rabbit antibodies (5 mg/liter) by a previously described method
(36). Observations were made with MRC1024 confocal scanning equipment
(Bio-Rad, Richmond, Calif.) mounted on an Axiovert confocal microscope (the
excitation wavelength was 495 nm and the emission wavelength was 519 nm for
green signals; the excitation wavelength was 578 nm and the emission wavelength
was 603 nm for red signals; Carl Zeiss, Oberkochen, Germany).
Reagents. Erythromycin was obtained as Erythrocine (erythromycin lactobion-
ate), which is the registered commercial product for intravenous administration
in Belgium and which was supplied by Abbott s.a., Ottignies-Louvain-la-Neuve,
Belgium. All other antibiotics were obtained as microbiological standards from
their corresponding manufacturers (azithromycin [dihydrate salt; potency,
94.4%] was from Pﬁzer Inc., Groton, Conn.; telithromycin [potency, 99.3%] and
roxithromycin [potency, 99.7%] were from Aventis Pharma, Romainville,
France; and clarithromycin [potency, 98.4%] was from Abbott Laboratories Ltd.,
Queenborough, England). Verapamil, cyclosporine, and 2-deoxyglucose were
products from Fluka Chemie, Buchs, Switzerland; GF120918 was kindly donated
by GlaxoWellcome Research and Development, Laboratoire GlaxoWellcome,
Les Ulis, France. Probenecid and gemﬁbrozil were supplied by Sigma-Aldrich
Chemie, Steinheim, Germany; monensin was from Sigma Chemical Co., St.
Louis, Mo.; cell culture media and serum were from Gibco Biocult (Paisley,
Scotland); rabbit polyclonal anti-P-glycoprotein (Ab-1) was from Oncogene,
Boston, Mass.; Alexa Fluor 488 anti-rabbit immunoglobulin G, LYBD, and
BCECF-AM were from Molecular Probes, Eugene, Oreg.; and all other reagents
were from E. Merck AG (Darmstadt, Germany).
Statistical analyses. Curve-ﬁtting analyses were done with GraphPad Prism
software (version 2.01; GraphPad Prism Software, San Diego, Calif.), and group
comparisons (Student’s t test, one-way analysis of variance) were done with Instat
Prism software (version 3.01; GraphPad Prism Software).
RESULTS
Inﬂuence of P-glycoprotein inhibitors on the kinetics of
macrolide accumulation and efﬂux. Figure 1A shows that
azithromycin (5 mg/liter) is gradually accumulated by J774
murine macrophages, with the levels reaching a plateau after
approximately 3 h (apparent cellular concentration-to-extra-
cellular concentration ratio, approximately 30-fold). Similar
kinetics were observed in the presence of verapamil (20 M,
added simultaneously with azithromycin); however, systemati-
cally higher levels of accumulation (2- to 3.5-fold) were ob-
tained at all time points (yielding an apparent cellular concen-
tration-to-extracellular concentration ratio at equilibrium of
approximately 100-fold). Similar observations were made in
the presence of 20 M cyclosporine and 2 M GF120918.
Unless stated otherwise, subsequent experiments were there-
fore performed with cells incubated for 3 h with the macrolides
under study (5 mg/liter) and with or without the P-glycoprotein
inhibitors. To examine azithromycin efﬂux, cells loaded with
this antibiotic (extracellular concentration, 20 mg/liter) in the
presence of inhibitors for 3 h were reincubated in antibiotic-
free medium in the continuing presence of the same inhibitors.
The same protocol was used for the controls, except that the
inhibitor was absent. Figure 1B shows that efﬂux was only
modestly impaired by verapamil, with a maximal effect at 5 h
FIG. 1. (A) Kinetics of uptake of azithromycin (extracellular concentration, 5 mg/liter) in J774 murine macrophages incubated for up to 24 h
in the absence (open squares) or in the presence (closed squares) of 20 M verapamil. (B) Efﬂux of azithromycin (extracellular concentration, 20
mg/liter) from J774 murine macrophages incubated for 3 h with azithromycin in the presence or absence of verapamil and then reincubated in an
azithromycin-free medium (chase). Open squares, controls; closed squares, cells incubated with 20 M verapamil during uptake and efﬂux
(half-lives for efﬂux, 50 min for the control and 53 min for verapamil, as calculated using one-phase exponential decay regression [Graph Pod Prism
software]). Results are expressed as the percentage of the drug remaining associated with the cells at the end of the loading period. All data are
the means  standard deviations of three experiments.
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controls). Yet, no signiﬁcant inﬂuence of verapamil could be
demonstrated over the short-term (1-h) or long-term (24-h)
treatment periods. Similar results were obtained with the two
other inhibitors (20 M cyclosporine and 2 M GF120918).
All these experiments were then repeated with telithromycin,
with similar results.
Dose effects of P-glycoprotein and MRP inhibitors on
azithromycin accumulation and comparison between macro-
lides. Figure 2A shows the results of experiments of the dose
effects of verapamil, cyclosporine, and GF120918 on the accu-
mulation of azithromycin at equilibrium. All three inhibitors
displayed similar maximal effects (approximately fourfold), but
with marked differences in potencies. In parallel experiments,
we also examined the inﬂuences of two known inhibitors of the
MRP efﬂux pump, namely, probenecid (2.5 mM) and gemﬁ-
brozil (0.25 mM), but did not observe any effect (data not
shown; the expression of the MRP1 efﬂux pump has been
demonstrated in J774 macrophages by Western blot analysis
[J. M. Michot, F. Van Bambeke, M. P. Mingeot-Leclercq, and
P. M. Tulkens, 40th Intersci. Conf. Antimicrob. Agents Che-
mother., abstr. 662, 2000]). In the next series of experiments,
we examined the inﬂuence of verapamil, cyclosporine, and
GF120918 at a ﬁxed concentration on the level of accumula-
tion of different macrolides. All antibiotics except erythromy-
cin were used at 5 mg/liter; for the detection of erythromycin,
it had to be present at 50 mg/liter due to its lower level of
accumulation (3). As observed in Fig. 2B, erythromycin and
telithromycin (with respect to cyclosporine and GF120918)
behaved essentially like azithromycin (the effect of verapamil
on telithromycin was, however, lower than those of the other
inhibitors tested). In sharp contrast, the accumulation of clar-
ithromycin was essentially unaffected. Roxithromycin showed
an intermediate behavior.
Inﬂuences of ATP depletion and cell exposure to monensin
on azithromycin accumulation. Because P-glycoprotein activ-
ity is ATP dependent, we examined the inﬂuence of ATP
depletion on azithromycin accumulation in cells (obtained by
preincubation of cells with 2-deoxyglucose and NaN3 and per-
formance of uptake studies in the presence of these inhibitors;
these conditions caused the cell ATP content to decrease to
about 10% of its original value). As shown in Table 1, ATP
depletion caused a marked increase in the level of azithromy-
cin accumulation, which was as important as that seen with 20
M verapamil. In parallel, cells were exposed to monensin, a
natural carboxylic ionophore known to dissipate transmem-
brane proton gradients in eucaryotic cells (35). As shown in
Table 1, monensin also almost completely suppressed the ac-
FIG. 2. (A) Azithromycin accumulation (extracellular concentra-
tion, 5 mg/liter) in J774 murine macrophages incubated for3hi nt h e
presence of increasing concentrations of P-glycoprotein inhibitors
(closed squares, verapamil; closed circles, cyclosporine (cyclosporin
A); closed triangles, GF120918). (B) Inﬂuence of P-glycoprotein in-
hibitors on cellular accumulation of macrolides in J774 murine mac-
rophages after3ho fincubation (closed bars, cyclosporine [20 M];
open bars, verapamil [20 M]; hatched bars, GF120918 [2 M]). The
extracellular concentration was 5 mg/liter for all macrolides except
erythromycin, which was 50 mg/liter. Results are expressed as the
percentage of the accumulation observed in the absence of inhibitor
(the cellular concentration-to-extracellular concentration ratios for the
controls were 20.7  3.7 for azithromycin, 2.7  0.1 for erythromycin,
16.3  1.4 for telithromycin, 19.3  1.7 for roxithromycin, and 46.6 
2.1 for clarithromycin; the values for azithromycin, erythromycin, and
roxithromycin are consistent with those observed previously [2, 3] with
the same cells but by use of radiolabeled drug). The effects of all
inhibitors on antibiotic accumulation were signiﬁcantly different (P 
0.05) for clarithromycin (CLR) compared to azithromycin (AZM),
erythromycin (ERY), or telithromycin (TEL) and for roxithromycin
(ROX) compared to azithromycin or erythromycin. The effect of ve-
rapamil on antibiotic accumulation was signiﬁcantly different (P 
0.05) from the effects of the other inhibitors for erythromycin, telithro-
mycin, and roxithromycin.
TABLE 1. Inﬂuence of an ATP-depleting treatment and monensin
on cellular accumulation of azithromycin in control J774
macrophages and in J774 macrophages
exposed to verapamil
a
Treatment
% Cellular accumulation
b
Control cells Cells exposed to verapamil
Control 100.0  7.8 287.6  20.4
ATP depletion
c 254.4  30.7 310.7  33.9
Monensin 5.9  1.0 3.4  0.6
a ATP depleting treatment was for 90 min, monensin (20 M) treatment was
for 3 h, azithromycin was used at a concentration of 5 mg/liter, and verapamil was
used at a concentration of 20 M. By statistical analysis (one-way analysis of
variance), P was 0.001 for control cells versus cells exposed to verapamil for the
control treatment, the control treatment versus ATP depletion for control cells,
and the control treatment versus monensin depletion for control cells.
b Percentage of the cellular accumulation observed in cells without any treat-
ment (azithromycin alone). Data are the means  standard deviations of three
experiments.
c ATP depletion was obtained by1ho fpreincubation in the presence of 60
mM 2-deoxyglucose and 5 mM NaN3; these conditions were maintained during
the incubation with azithromycin.
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incubated with verapamil.
Inﬂuence of verapamil on lysosomal and cytoplasmic pHs.
We examined whether verapamil could increase the levels of
macrolide accumulation by perturbing the pH gradient be-
tween the extracellular milieu and the lysosomes. This was
investigated by using speciﬁc ﬂuorescent tracers, the excitation
spectra of which vary with a change in the pH (lysosensor
yellow/blue-labeled dextran for lysosomes and BCECF for the
cytosol; see Materials and Methods). No signiﬁcant change
from the control values was observed (pHs, 7.06  0.93 [n 
17] and 4.95  0.13 [n  35] for the cytosol and lysosomes in
the controls, respectively).
Localization of immunoreactive P-glycoprotein. As shown in
Fig. 3, anti-P-glycoprotein antibodies gave a faint pericellular
labeling (plasma membrane), together with marked staining of
discrete cytoplasmic granules of various sizes and a perinuclear
distribution. Rhodamine-labeled dextran almost exclusively
stained cytoplasmic granules. When merged images were ex-
amined, a large proportion of these granules turned yellow,
demonstrating a partial common subcellular localization of
rhodamine-labeled dextran and anti-P-glycoprotein antibodies.
DISCUSSION
The data presented in the paper disclose that verapamil,
cyclosporine, and GF120918 markedly increase the cellular
accumulation of the macrolide antibiotics azithromycin, eryth-
romycin, and telithromycin in a model of J774 murine macro-
phages. The accumulation of roxithromycin is less affected, and
the accumulation of clarithromycin showed no signiﬁcant
change. Verapamil and cyclosporine are known to inhibit the
mammalian P-glycoprotein and to affect several other cell
functions (15). In contrast, GF120918 is a much more speciﬁc
inhibitor of P-glycoprotein and is not known, so far, to have
other signiﬁcant pharmacological properties (for reviews, see
references 15 and 11). We have also shown that J774 macro-
phages express an immunoreactive P-glycoprotein, with a dis-
tribution consistent with what has been described in other cells
(i.e., a partial localization at the cell surface, with a large
quantity belonging to intracellular pools [the role of which is to
maintain a constant amount of the active protein at the cell
surface] [16]). All together, these data strongly suggest that
modulation of P-glycoprotein is responsible for the observed
effects on the accumulation of azithromycin, erythromycin, and
telithromycin.
Macrolide accumulation in cells is dependent upon trans-
membrane pH gradients, which cause these drugs to be pref-
erentially sequestered in lysosomes and related acidic vacuoles
(2, 3; see also our data with monensin). A ﬁrst hypothesis could
therefore be that P-glycoprotein inhibitors increase the pH
gradient between lysosomes and the extracellular milieu and/or
the cytosol, either directly or by modulating P-glycoprotein
basal activity (pH gradients between cell compartments are
indeed reduced upon overexpression of efﬂux transporters
[16]). This hypothesis can be ruled out since we did not observe
signiﬁcant changes in lysosomal and cytosolic pHs after expo-
sure to verapamil. Moreover, the pH variations induced by
inhibitors should have affected the accumulation of all macro-
lides. A second and more likely hypothesis, therefore, is that
P-glycoprotein defeats the cellular accumulation of certain
macrolides because of its drug efﬂux capabilities. This hypoth-
esis is consistent with our observation that ATP depletion is as
effective as the addition of a P-glycoprotein inhibitor (P-glyco-
protein is dependent upon ATP for activity) (for reviews, see
references 27 and 28). It also explains why macrolides with only
minor chemical differences (viz., clarithromycin versus eryth-
romycin) may have markedly different sensitivities to inhibi-
tors. Substrate recognition by P-glycoprotein is indeed known
to be highly variable even between drugs that are very closely
related chemically, and deﬁned pharmacophores are still far
from being clearly recognized, apart from their general prop-
erties related to their lipophilicities and sizes (32). It is intrigu-
ing, however, that P-glycoprotein inhibitors do not markedly
inﬂuence macrolide efﬂux. Biophysical studies actually suggest
that P-glycoprotein binds to its substrates from within the
membrane and not from the cytosol, acting as a ﬂippase (10) or
a “vacuum cleaner” (27). In this type of model, a lower level of
cell accumulation results more from a decreased inﬂux than
from an increased net efﬂux (6, 8), as substrates need not have
access to the cytosol to be extruded (18). Experimental testing
of this model for macrolides could be done by using sublines of
J774 macrophages overexpressing the P-glycoprotein or appro-
priate reconstituted membrane models.
The present experiments have been limited to J774 macro-
phages, which were used as a model, and generalization of our
conclusions to other phagocytic cells therefore remains unwar-
ranted. In particular, the presence of a functional P-glycopro-
tein and its potential role in macrolide handling in polymor-
phonuclear leukocytes are controversial (4, 14, 21, 38). It is
interesting, however, that human KB and G-185 cells overex-
pressing P-glycoprotein show decreased levels of macrolide
accumulation and correspondingly reduced levels of antimicro-
bial activity against intracellular forms of Listeria monocyto-
FIG. 3. Confocal ﬂuorescence microscopy. (A) Phase-contrast microscopy; (B) green channel, with immunological detection of P-glycoprotein
with rabbit polyclonal anti-P-glycoprotein antibodies (12.5 mg/liter) and Alexa Fluor 488-labeled secondary antibodies (5 mg/liter); (C) red
channel, with vital staining of lysosomes and endosomes with rhodamine-B labeled dextran (2.5 mg/ml; the cells were incubated overnight with the
tracer prior to their ﬁxation and subsequent labeling with the anti-P-glycoprotein antibodies); (D) merged images.
1050 SERAL ET AL. ANTIMICROB.A GENTS CHEMOTHER.genes (22). The inﬂuences of efﬂux proteins on cellular han-
dling of macrolides and their effects on the intracellular
activities of these antibiotics may therefore need to be studied
systematically.
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